Perceval S Aortic Heart Valve Study- North America

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01810679

Recruitment Status : Terminated (FDA approval)

First Posted : March 13, 2013

Last Update Posted : November 16, 2016

Sponsor:

Information provided by (Responsible Party):

Sorin Group USA, Inc.

Study Description

Brief Summary:

To demonstrate the safety and effectiveness of the Perceval S heart valve when used to replace a diseased or dysfunctional aortic valve or aortic valve prosthesis.

Condition or disease	Intervention/treatment	Phase
Aortic Valve Stenosis Aortic Valve Stenosis With Insufficiency Regurgitation, Aortic Valve Aortic Valve Incompetence	Device: Perceval S Aortic Heart Valve	Not Applicable

Detailed Description:

This investigation is a prospective, non-randomized, multi-center trial of the PERCEVAL valve implanted in patients requiring aortic valve replacement. The study will be conducted in a maximum of 25 centers in the United States. Patients will be evaluated at each of the following time intervals:preoperative, at implant, in the early postoperative period, in the late postoperative period (between 3 and 6 months postoperatively), at 1 year (between 11 and 13 months postoperatively), and annually until study completion. The duration of the study is anticipated to be 5 years.

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	355 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Clinical Investigation of the Perceval S Sutureless Heart Valve
Study Start Date :	April 2013
Actual Primary Completion Date :	February 2016
Estimated Study Completion Date :	April 2018

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Supravalvular aortic stenosis

Genetic and Rare Diseases Information Center resources: Aortic Valve Stenosis

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Perceval S Aortic Heart Valve Treatment with the Perceval S Aortic Heart Valve	Device: Perceval S Aortic Heart Valve Perceval S Sutureless Aortic Heart Valve

Outcome Measures

Primary Outcome Measures :

Primary Safety Endpoint [ Time Frame: One-year ]
To demonstrate that the complication and survival rates for the PERCEVAL S valve are comparable to appropriate historical controls manifested as objective performance criteria (OPCs) and to that reported for other stented bioprostheses in the literature
Primary Efficacy Endpoint [ Time Frame: One-year ]
To demonstrate that the rate of valve success for the PERCEVAL S valve is comparable to that of appropriate historical controls

Secondary Outcome Measures :

Secondary Efficacy Outcomes [ Time Frame: One-year ]
To demonstrate that the hemodynamic performance of the PERCEVAL S valve is comparable to that reported in the literature for other stented aortic bioprostheses
Secondary Efficacy Outcomes [ Time Frame: One-year ]
To demonstrate clinically significant improvements in overall patient condition by comparison of preoperative and postoperative NYHA functional classifications
Secondary Efficacy Outcomes [ Time Frame: One-year ]
To demonstrate that the rate of device technical success for the PERCEVAL S valve is comparable to that of appropriate historical controls

Other Outcome Measures:

Supplementary Analyses [ Time Frame: Discharge ]
Rates of cross-clamp time, cardiopulmonary bypass time, length of stay in ICU, length of hospital, and quality of life

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Subjects of age >= 18 years.
Subjects with aortic valve stenosis or steno-insufficiency.
The subject is willing to sign the informed consent.
The subject in which preoperative evaluation indicated the need for native or prosthetic aortic valve replacement.
The subject is located in a geographic location that will enable the subject to return to the study site for all follow-up examinations (i.e. geographically stable).
Subject will be available to the investigator(s) for postoperative follow-up beyond one year.

Exclusion criteria:

The subject has preexisting valve prosthesis or annuloplasty ring in the mitral, pulmonic or tricuspid position.
The subject requires a double or multiple valve replacement or repair of the mitral, tricuspid, or pulmonic valve.
The subject has a previously implanted PERCEVAL valve that requires replacement.
Subjects requiring simultaneous cardiac procedures, apart from septal myectomy and/or coronary by-pass.
The subject has active endocarditis.
Subjects with active myocarditis
The subject is or will be participating in a concomitant research study of an investigational product.
Subjects with aneurysmal dilation or dissection of the ascending aortic wall.
The subject is a minor, drug abuser, alcohol abuser, prison inmate, institutionalized, or is unable to give informed consent.
The subject has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the patient.
Subjects with known hypersensitivity to nickel alloys.
The subject is undergoing renal dialysis for chronic renal failure or has hyperparathyroidism.
The subject has had an acute preoperative neurological deficit, myocardial infarction, or cardiac event that has not returned to baseline or stabilized ≥30 days prior to the planned valve implant surgery.
Subject is known to be noncompliant or is unlikely to complete the study.
Subjects with an aortic root enlargement, where the ratio between the diameter of the sino-tubular junction and the annulus diameter, assessed by TTE, is > 1.3.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01810679

Show 21 Study Locations

Sponsors and Collaborators

Sorin Group USA, Inc.

Investigators


Principal Investigator:	Rakesh Suri, MD, DPhil	The Cleveland Clinic

More Information


Responsible Party:	Sorin Group USA, Inc.
ClinicalTrials.gov Identifier:	NCT01810679 History of Changes
Other Study ID Numbers:	G120053
First Posted:	March 13, 2013 Key Record Dates
Last Update Posted:	November 16, 2016
Last Verified:	November 2016

Keywords provided by Sorin Group USA, Inc.:


aortic valve replacement aortic stenosis aortic steno-insufficiency Perceval Sutureless aortic heart valve

Additional relevant MeSH terms:


Constriction, Pathologic Aortic Valve Stenosis Aortic Valve Insufficiency Pathological Conditions, Anatomical	Heart Valve Diseases Heart Diseases Cardiovascular Diseases Ventricular Outflow Obstruction

To Top